We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Effects of Matuzumab in Combination With Pemetrexed for the Treatment of Advanced Lung Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00111839
Recruitment Status : Completed
First Posted : May 27, 2005
Last Update Posted : March 10, 2017
Sponsor:
Information provided by:
EMD Serono

Brief Summary:

This study is planned to answer questions about how the drug, matuzumab (EMD 72000), works and is part of an effort aimed to develop better treatment for advanced lung cancer by combining matuzumab, a monoclonal antibody, with a chemotherapy treatment, called pemetrexed. Pemetrexed is commercially available and has been approved for treatment of locally advanced or metastatic non-small cell lung cancer that could not be successfully treated with other chemotherapy.

The study aims to examine how non-small cell lung cancer (NSCLC) responds to matuzumab in combination with pemetrexed, as compared with giving pemetrexed alone. The study also aims to examine how safe and effective matuzumab is and for how long it stays in the body (pharmacokinetics). Matuzumab is an experimental treatment which is currently only available for research studies.


Condition or disease Intervention/treatment Phase
Lung Cancer Non Small Cell Lung Carcinoma Drug: Pemetrexed Drug: Matuzumab + Pemetrexed Phase 2

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 153 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Randomized, Phase II,Open-Label Controlled Study of Two Different Doses and Schedules of EMD 72000 (Matuzumab) in Combination With Pemetrexed, or Pemetrexed Alone, as Second-Line Treatment for Stage IIIB/IV Non-Small Cell Lung Cancer and Progressive Disease on or After First-Line Treatment With a Platinum in Combination With Taxanes, Gemcitabine and Vinorelbine
Study Start Date : May 2005
Primary Completion Date : July 2007
Study Completion Date : March 2009

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Lung Cancer
U.S. FDA Resources

Arm Intervention/treatment
Active Comparator: 1 Drug: Pemetrexed
pemetrexed 500mg per metre squared given i.v. (into the vein) every 3 weeks until progression of disease or unacceptable toxicity
Experimental: 2 Drug: Matuzumab + Pemetrexed
matuzumab 800mg given i.v. every week plus pemetrexed as in Group 1 until progression of disease or unacceptable toxicity
Experimental: 3 Drug: Matuzumab + Pemetrexed
matuzumab 1600mg given i.v. every 3 weeks plus pemetrexed as in Group 1 until progression of disease or unacceptable toxicity



Primary Outcome Measures :
  1. Independent radiological response rate [ Time Frame: various timepoints measured ]

Secondary Outcome Measures :
  1. Overall Survival [ Time Frame: various timepoints measured ]
  2. Time to tumor progression [ Time Frame: various timepoints measured ]
  3. Duration of response [ Time Frame: various timepoints measured ]
  4. Safety and tolerability [ Time Frame: various timepoints measured ]
  5. Quality of life [ Time Frame: various timepoints measured ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Written informed consent provided prior to any screening procedure
  • Male or female,> 18 years of age
  • Histologically or cytologically confirmed diagnosis of non-small cell lung cancer
  • Demonstrated progressive disease on or after first-line chemotherapy for stage IIIB/IV disease. The first-line therapy must consist of platinum-based regimens in combination with taxanes,gemcitabine or vinorelbine.. Stage IIIB/IV patients must have measurable disease (tumor) without clinically significant pleural unless the pleural effusion can be effectively drained prior to admission into the study.
  • A chemotherapy-free interval of at least 3 weeks between the end of first-line chemotherapy and start of study treatment
  • At least 1 measurable lesion according to the modified WHO criteria
  • Archived tissue or cytologic sample available for the determination of EGFR expression
  • ECOG performance status 0-1
  • Life expectancy >12 weeks
  • Adequate baseline organ functions, defined as follows: *Serum creatinine ≤1.5 × upper limit of normal (ULN). In case of borderline values for serum creatinine, creatinine clearance must be ≥45 mL/min; *Total bilirubin <1.5 × ULN; *Alanine aminotransferase (ALT)/aspartate aminotransferase (AST) ≤2.5 × ULN (Subjects with liver metastases should have ALT/AST <5 × ULN.); *Absolute neutrophil count ≥1500/mm3; *Platelet count ≥100,000/mm3; *Hemoglobin level ≥10 g/dL11
  • If procreative potential (male or female), willingness to use effective contraceptive methods for the duration of treatment and continuing for 2 months after the last dose. Subjects of procreative potential are defined as any fertile male, or any female who has experienced menarche and who is not postmenopausal (defined as age-related amenorrhea ≥12 months) or who has not undergone successful surgical sterilization (hysterectomy or bilateral oophorectomy)

Exclusion Criteria:

  • Radiotherapy or major surgery within 30 days prior to the start of study treatment
  • Prior treatment with an EGFR-directed therapy or with EGFR signal transduction inhibitors
  • Prior treatment with pemetrexed
  • Pregnant (confirmed by β-HCG) or lactating female
  • Weight loss >10% within 12 weeks prior to the start of study treatment
  • Documented or symptomatic brain metastases or leptomeningeal disease
  • Myocardial infarction within 6 months prior to the start of study treatment, uncontrolled congestive heart failure, or any current New York Heart Association Grade III or IV cardiovascular disorder despite treatment
  • Presence of a ≥Grade 2 preexisting skin disorder (except for alopecia)
  • Previous diagnosis of autoimmune disease with significant organ involvement
  • Concurrent malignancies or invasive carcinomas diagnosed within the past 5 years, except for adequately treated basal cell carcinoma of the skin or in situ carcinoma of the cervix
  • Any significant disease that, in the Investigator's opinion, should exclude the subject from the study
  • History of significant neurologic or psychiatric disorder (e.g., dementia, seizures, or bipolar disorder)
  • History of drug abuse within 6 months prior to the start of study treatment
  • Known conditions that require concurrent treatment with a nonpermitted drug
  • Presence of a contraindication to the study treatment(s) according to the current Investigator's Brochure (IB) for matuzumab and the labeling for pemetrexed
  • Known hypersensitivity to the study treatment or any of its components
  • Participation in another clinical study within 30 days prior to the start of study treatment

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00111839


  Show 58 Study Locations
Sponsors and Collaborators
EMD Serono
Investigators
Principal Investigator: Joan Schiller, MD University of Texas
Principal Investigator: Mark Socinski, MD University of North Carolina, Chapel Hill

Additional Information:
Publications:
Responsible Party: Claire Beadman, Merck KGaA
ClinicalTrials.gov Identifier: NCT00111839     History of Changes
Other Study ID Numbers: EMD 72000-031
First Posted: May 27, 2005    Key Record Dates
Last Update Posted: March 10, 2017
Last Verified: March 2017

Keywords provided by EMD Serono:
Lung cancer

Additional relevant MeSH terms:
Lung Neoplasms
Carcinoma, Non-Small-Cell Lung
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Neoplasms
Lung Diseases
Respiratory Tract Diseases
Carcinoma, Bronchogenic
Bronchial Neoplasms
Pemetrexed
Antineoplastic Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Folic Acid Antagonists
Nucleic Acid Synthesis Inhibitors